Broad Respiratory Antiviral (Tripledemic Inhibitor)

About Salarius Pharmaceuticals

Decoy Therapeutics, operating under the former shell of Salarius Pharmaceuticals, has executed a strategic pivot from oncology to infectious disease, now focused on engineering broad-spectrum antiviral therapeutics. Its core mission is to overcome the limitations of narrow, single-pathogen treatments by developing Designable Multi-Antivirals (DMAVs) that target conserved viral entry mechanisms across entire viral families. The company's strategy is underpinned by the IMP³ACT platform, which uses AI-driven design and rapid synthesis to create peptide conjugates, with lead programs in preclinical development for pan-coronavirus and tripledemic indications. Key achievements include strategic partnerships for AI/cloud infrastructure and a commitment to developing a globally accessible manufacturing platform.

Therapeutic Areas